![](https://www.eurekalert.org/images/EurekAlert-bluebg_Twitter_601X601.png)
MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab
HOUSTON and MIAMI ― The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab. Leveraging MD Anderson’s …